Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alessia Bianchi

Showing results (31-40 of 48) with videos related to

Pageof 5
Sort By:
Brain and Behavior|November 27, 2025
The ABILHAND-23 Patient Reported Outcome Measure in Secondary Progressive Multiple Sclerosis: A Cross-Sectional Analysis With the Nine Hole Peg TestSean Apap Mangion, Charles Wade, Tom Williams, et al.
Brain Communications|June 30, 2025
The temporal dynamics and clinical relevance of choroid plexus measures in multiple sclerosisErmelinda De Meo, Sarmad Al-Araji, Baris Kanber, et al.
Neurology|October 3, 2022
Differentiating Multiple Sclerosis From AQP4-Neuromyelitis Optica Spectrum Disorder and MOG-Antibody Disease With ImagingRosa Cortese, Ferran Prados Carrasco, Carmen Tur, et al.
European Journal of Neurology|June 15, 2023
Cardiovascular risk factors in secondary progressive multiple sclerosis: A cross-sectional analysis from the MS-STAT2 randomized controlled trialThomas Williams, Nevin John, Alberto Calvi, et al.
Brain Communications|July 13, 2026
Investigating the treatment of vascular risk with simvastatin in secondary progressive multiple sclerosis: analysis from the MS-STAT2 randomized controlled trialThomas Williams, Nicholas Magill, Nevin A John, et al.
Neuroimage. Reports|September 27, 2024
Investigating the relationship between thalamic iron concentration and disease severity in secondary progressive multiple sclerosis using quantitative susceptibility mapping: Cross-sectional analysis from the MS-STAT2 randomised controlled trialThomas Williams, Nevin John, Alberto Calvi, et al.
BMJ Open|September 25, 2025
Single-centre, prospective cohort to predict optimal individualised treatment response in multiple sclerosis (POINT-MS): a cohort profileRonja Christensen, Alessandro Cruciani, Sarmad Al-Araji, et al.
BMJ Neurology Open|December 22, 2025
Immunogenicity of three-dose COVID-19 vaccines in people living with multiple sclerosisMarianne J Shawe-Taylor, David Greenwood, Anna He, et al.
Journal of Neurology|February 17, 2024
The role of ethnicity and native-country income in multiple sclerosis: the Italian multicentre study (MS-MigIT)Alessia Bianchi, Domenica Matranga, Francesco Patti, et al.
Neurology|August 7, 2025
Effectiveness of Disease-Modifying Therapies in Patients With Late-Onset Relapsing-Remitting Multiple SclerosisSarmad Al-Araji, Marcello Moccia, Ashwani Jha, et al.
Pageof 5

Showing results (31-40 of 48) with videos related to

Sort By:
Pageof 5
Brain and Behavior|November 27, 2025
The ABILHAND-23 Patient Reported Outcome Measure in Secondary Progressive Multiple Sclerosis: A Cross-Sectional Analysis With the Nine Hole Peg TestSean Apap Mangion, Charles Wade, Tom Williams, et al.
Brain Communications|June 30, 2025
The temporal dynamics and clinical relevance of choroid plexus measures in multiple sclerosisErmelinda De Meo, Sarmad Al-Araji, Baris Kanber, et al.
Neurology|October 3, 2022
Differentiating Multiple Sclerosis From AQP4-Neuromyelitis Optica Spectrum Disorder and MOG-Antibody Disease With ImagingRosa Cortese, Ferran Prados Carrasco, Carmen Tur, et al.
European Journal of Neurology|June 15, 2023
Cardiovascular risk factors in secondary progressive multiple sclerosis: A cross-sectional analysis from the MS-STAT2 randomized controlled trialThomas Williams, Nevin John, Alberto Calvi, et al.
Brain Communications|July 13, 2026
Investigating the treatment of vascular risk with simvastatin in secondary progressive multiple sclerosis: analysis from the MS-STAT2 randomized controlled trialThomas Williams, Nicholas Magill, Nevin A John, et al.
Neuroimage. Reports|September 27, 2024
Investigating the relationship between thalamic iron concentration and disease severity in secondary progressive multiple sclerosis using quantitative susceptibility mapping: Cross-sectional analysis from the MS-STAT2 randomised controlled trialThomas Williams, Nevin John, Alberto Calvi, et al.
BMJ Open|September 25, 2025
Single-centre, prospective cohort to predict optimal individualised treatment response in multiple sclerosis (POINT-MS): a cohort profileRonja Christensen, Alessandro Cruciani, Sarmad Al-Araji, et al.
BMJ Neurology Open|December 22, 2025
Immunogenicity of three-dose COVID-19 vaccines in people living with multiple sclerosisMarianne J Shawe-Taylor, David Greenwood, Anna He, et al.
Journal of Neurology|February 17, 2024
The role of ethnicity and native-country income in multiple sclerosis: the Italian multicentre study (MS-MigIT)Alessia Bianchi, Domenica Matranga, Francesco Patti, et al.
Neurology|August 7, 2025
Effectiveness of Disease-Modifying Therapies in Patients With Late-Onset Relapsing-Remitting Multiple SclerosisSarmad Al-Araji, Marcello Moccia, Ashwani Jha, et al.
Pageof 5